Therefore, miR-222-3p was overexpressed in ERα-negative endometrial carcinoma tumors and was associated with high grade, late stage, and nodal metastasis, and high level of miR-222-3p was a mechanism for raloxifene resistance in endometrial carcinoma therapy. The gene discussed is ESR1; the disease is endometrial carcinoma.